Halley E Gilbert sold $455k of ARQT
director at Arcutis Biotherapeutics, Inc.. 16,532 shares at an average of $27.55, traded Nov 20, 2025, filed Nov 21, 2025.
Score components
- +15RoleDirector
- +17Trade size$455k at market
- +10Share of holdings soldSold 43% of holdings
- +15Cluster8 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -5.0%, 3m -13.8%, 6m -29.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001601360-25-000007, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 20, 2025 | MOption exercise Common Stock | +12,220 | $7.51 | $92k | 38,655 | Nov 21, 2025 |
| Nov 20, 2025 | SOpen-market sale Common Stock | -16,532 | $27.55 | $455k | 22,123 | Nov 21, 2025 |
| Nov 20, 2025 | MOption exercise Stock Option (right to buy)derivative | -12,220 | $0.00 | $0 | 0 | Nov 21, 2025 |
Related signals
Other insiders at Arcutis Biotherapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 12Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $92k 3,674 shares | -3% | |
| 3Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $114k 4,730 shares | -12% | |
| 23Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $250k 9,989 shares | -8% | |
| 59Moderate | Arcutis Biotherapeutics, Inc. | Terrie Curran director | $956k 38,200 shares | -110% | |
| 20Weak | Arcutis Biotherapeutics, Inc. | Terrie Curran director | $28k 1,072 shares | -4% | |
| 36Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $46k 1,697 shares | -1% | |
| 10Weak | Arcutis Biotherapeutics, Inc. | Howard G. Welgus director | $124k 4,730 shares | -11% | |
| 36Weak | Arcutis Biotherapeutics, Inc. | Patrick Burnett See Remarks | $395k 15,000 shares | -12% | |
| 20Weak | Arcutis Biotherapeutics, Inc. | Todd Franklin Watanabe See Remarks | $114k 4,375 shares | -1% | |
| 15Weak | Arcutis Biotherapeutics, Inc. | Masaru Matsuda See Remarks | $32k 1,230 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.